Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Summary
Moderna has secured European Commission marketing authorization for mCOMBRIAX, its mRNA combination vaccine targeting influenza and COVID-19 in individuals 50 and older. This approval is highly significant as mCOMBRIAX is the world's first flu plus COVID-19 combination vaccine to receive such clearance, valid across the EU and associated countries. The new product strengthens Moderna's respiratory portfolio and offers a crucial new revenue opportunity, especially in light of the company's recent 10-K reporting revenue declines and pipeline setbacks. Based on strong Phase 3 trial results, this authorization allows Moderna to simplify immunization for high-risk adults. Investors will now monitor the company's progress in national regulatory and access procedures to assess the vaccine's market rollout and sales potential.
At the time of this announcement, MRNA was trading at $53.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.